Transcatheter heart valve explant with infective endocarditis-associated prosthesis failure and outcomes: the EXPLANT-TAVR international registry
Mateo Marin-Cuartas,Gilbert H L Tang,Philipp Kiefer,Shinichi Fukuhara,Rudiger Lange,Katherine B Harrington,Shekhar Saha,Christian Hagl,Neal S Kleiman,Sachin S Goel,Joerg Kempfert,Paul Werner,George A Petrossian,Arnar Geirsson,Nimesh D Desai,Michael W A Chu,Oliver D Bhadra,Christian Shults,Andrea Garatti,Flavien Vincent,Kendra J Grubb,Joshua B Goldberg,Michael J Mack,Thomas Modine,Paolo Denti,Tsuyoshi Kaneko,Vinayak N Bapat,Michael J Reardon,Michael A Borger,Syed Zaid,Giuseppe Bruschi,John J Squiers,Molly I Szerlip,J Michael DiMaio,Sameer Hirji,Pinak B Shah,Lionel Leroux,Eric Van Belle,Mohammad Koussa,Tamim M Nazif,Isaac George,Nicholas M Van Mieghem,Thijmen W Hokken,Axel Unbehaun,Keti Vitanova,Marvin D Atkins,John R Doty,Brian K Whisenant,Marco Di Eusanio,Filippo Capestro,Basel Ramlawi,David Holzhey,Thilo Noack,Luigi Pirelli,Derek R Brinster,Muhanad Algadheeb,Rodrigo Bagur,Antonio Di Virgilio,Michael H Salinger,Martin Andreas,Lowell F Satler,Ron Waksman,Walid Ben Ali,Reda Ibrahim,Philippe Demers,Joshua Rovin,Pierre Voisine,Siamak Mohammadi,Josep Rodés-Cabau,Guido Gelpi,Igor Belluschi,Francesco Maisano,Newell B Robinson,Lin Wang,Maral Ouzounian,Lenard Conradi,Rodrigo Estevez-Loureiro,Miguel A Pinon,Moritz Wyler von Ballmoos,Tom C Nguyen,G Michael Deeb,Marc Ruel,Talal Al-Atassi,Augusto D'Onofrio,Chiara Tessari,Joseph E Bavaria,Andrea Colli,Alejandro Pizano,Kashish Goel,Ashish S Shah,Hasan A Ahmad,John K Forrest,Maurizio Taramasso,Marco Gennari,EXPLANT-TAVR Investigators
DOI: https://doi.org/10.1093/eurheartj/ehae292
IF: 39.3
2024-06-02
European Heart Journal
Abstract:Surgical explantation of transcatheter heart valves (THVs) is rapidly increasing, but there are limited data on patients with THV-associated infective endocarditis (IE). This study aims to assess the outcomes of patients undergoing THV explant for IE. All patients who underwent THV explant between 2011 and 2022 from 44 sites in the EXPLANT-TAVR registry were identified. Patients with IE as the reason for THV explant were compared to those with other mechanisms of bioprosthetic valve dysfunction (BVD). A total of 372 patients from the EXPLANT-TAVR registry were included. Among them, 184 (49.5%) patients underwent THV explant due to IE and 188 (50.5%) patients due to BVD. At the index transcatheter aortic valve replacement, patients undergoing THV explant for IE were older (74.3 ± 8.6 vs. 71 ± 10.6 years) and had a lower Society of Thoracic Surgeons risk score [2.6% (1.8–5.0) vs. 3.3% (2.1–5.6), P = .029] compared to patients with BVD. Compared to BVD, IE patients had longer intensive care unit and hospital stays ( P < .05) and higher stroke rates at 30 days (8.6% vs. 2.9%, P = .032) and 1 year (16.2% vs. 5.2%, P = .010). Adjusted in-hospital, 30-day, and 1-year mortality was 12.1%, 16.1%, and 33.8%, respectively, for the entire cohort, with no significant differences between groups. Although mortality was numerically higher in IE patients 3 years postsurgery (29.6% for BVD vs. 43.9% for IE), Kaplan–Meier analysis showed no significant differences between groups ( P = .16). In the EXPLANT-TAVR registry, patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate, which did not reach statistical significance given the relatively small sample size of this unique cohort and the reduced number of events. A total of 372 patients from the EXPLANT-TAVR registry were analysed. Among them, 184 (49.5%) patients underwent transcatheter heart valve (THV) explant due to infective endocarditis (IE) and 188 (50.5%) patients due to bioprosthetic valve dysfunction (BVD). Patients undergoing THV explant for IE had higher 30-day and 1-year stroke rates and longer intensive care unit (ICU) and hospital stays. Moreover, patients undergoing THV explant for IE had a higher 3-year mortality rate. BEV, balloon-expandable valve; IQR, interquartile range; TAVR, transcatheter aortic valve replacement.
cardiac & cardiovascular systems